Anthera Pharmaceuticals
Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company developing blisibimod and related therapeutics for inflammatory and autoimmune diseases; pre-revenue, publicly traded on OTC pink sheets, and operating with a small Hayward-based team.
- Company typePrivate
- Founded2004
- HeadquartersHayward, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Anthera Pharmaceuticals does
Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Hayward, California, founded in 2004 and publicly traded on the OTC pink sheets under the symbol ANTH. The company is focused exclusively on developing therapeutics to treat diseases associated with inflammation and autoimmune conditions. Its most advanced program is blisibimod, a B-lymphocyte stimulator (BLyS / BAFF) inhibitor intended to modulate B-cell activity in immune-mediated disease.
The company has financed its operations through multiple private equity rounds from a syndicate of specialty life-sciences investors, including Sofinnova Investments, VantagePoint Capital Partners, Pappas Ventures, Caxton Associates, HBM Healthcare Investments, Mitsubishi International Corporation, OrbiMed, and others. Cumulative disclosed equity funding totals approximately $101.5 million across rounds in 2006, 2008, 2010, and 2018. Anthera has not yet reached commercial revenue generation, and the company's public market valuation is extremely low, with shares trading at $0.0001 — a level typical of distressed micro-cap biotech.
Anthera operates with a small team (11-50 employees) and a leadership group that includes a board chairman, president/COO, CTO functions, and a senior vice president of finance. There is no disclosed commercialization infrastructure, marketing, or distribution capability in the source data, consistent with a pre-commercial clinical-stage entity whose only material asset is its blisibimod development program. (Note: a separate "Anthera Cosmetics" entity appearing in the source data is an unrelated French private cosmetics brand and is explicitly flagged in the source as a different company.)
Anthera Pharmaceuticals firmographics
Firmographics- Name
- Anthera Pharmaceuticals
- Legal name
- ANTHERA COSMETICS
- Website
- https://anthera.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company developing blisibimod and related therapeutics for inflammatory and autoimmune diseases; pre-revenue, publicly traded on OTC pink sheets, and operating with a small Hayward-based team.
- Ownership category
- akta.pro rank
Anthera Pharmaceuticals industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Anthera Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Hayward
- HQ country
- United States
- HQ region
- North America
Markets served
Anthera Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Anthera Pharmaceuticals product offering
Product offeringCore offering
Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics to treat diseases associated with inflammation and autoimmune diseases. The company's most advanced asset is blisibimod, which anchors its pipeline in the immunology therapeutic area. The company is publicly traded on OTC Pink under the symbol ANTH (otcpink:ANTH).
Differentiator
Problem solved
Functional benefit
Products and services
- blisibimod Anthera Pharmaceuticals' most advanced clinical-stage asset, developed for the treatment of inflammatory and autoimmune diseases, anchored as the company's lead therapeutic program.
Companies that use Anthera Pharmaceuticals
Customer profileIdeal customer profiles1 record
Anthera Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Anthera Pharmaceuticals partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights3 records
Anthera Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- AbbVie: Large-cap biopharma with the leading franchise in autoimmune/inflammation (Humira, Skyrizi, Rinvoq). A potential acquirer of late-stage autoimmune assets like blisibimod.
- Amgen: Major biopharma with deep inflammation/autoimmune portfolio (Enbrel, Otezla, Tezspire). A natural strategic acquirer for B-cell pathway assets.
- Bristol-Myers Squibb: Large biopharma with significant autoimmune and immunology franchises and a history of acquiring mid-stage inflammation assets. Strategic acquirer comparable.
Direct peers
- AnaptysBio: Clinical-stage immunology biotech developing antibodies for autoimmune and inflammatory diseases. Comparable in therapeutic focus and small-cap public profile to Anthera.
- Provention Bio: Specialty biotech focused on immune-mediated diseases including autoimmune indications. Comparable as a small public clinical-stage immunology company.
- Arcturus Therapeutics: Clinical-stage biotech developing RNA-based therapeutics for rare diseases including inflammatory indications. Comparable small public clinical-stage biotech profile.
- Coherus Biosciences: Biologics-focused company developing immunology therapeutics including biosimilars and novel immuno-oncology agents. Comparable therapeutic focus on inflammation/immunology.
- Dice Therapeutics (acquired by Eli Lilly): Clinical-stage immunology company developing oral small molecules for chronic autoimmune diseases. Comparable as a small-cap immunology biotech that ultimately was acquired.
- Arena Pharmaceuticals (acquired by Pfizer): Mid-stage immunology/GI biotech acquired by Pfizer. Relevant comparable for a small-cap inflammation-focused public biopharma.
- Viela Bio (acquired by Horizon Therapeutics): Autoimmune-disease specialist biotech that developed therapeutics for inflammation conditions, eventually acquired. Illustrates the M&A exit path relevant to Anthera.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Anthera Pharmaceuticals social profiles
Digital presenceAnthera Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Anthera Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles6 records
Anthera Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds5 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Anthera Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Anthera Pharmaceuticals
What does Anthera Pharmaceuticals do?
Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics to treat diseases associated with inflammation and autoimmune diseases. The company's most advanced asset is blisibimod, which anchors its pipeline in the immunology therapeutic area. The company is publicly traded on OTC Pink under the symbol ANTH (otcpink:ANTH).
Is Anthera Pharmaceuticals a public or private company?
Anthera Pharmaceuticals is a private company. It is classified as public and is currently operating.
When was Anthera Pharmaceuticals founded?
Anthera Pharmaceuticals was founded in 2004. It employs 11 to 50 people.
Where is Anthera Pharmaceuticals based?
Anthera Pharmaceuticals is headquartered in Hayward, United States, in the North America region.
Who are Anthera Pharmaceuticals's main competitors?
Broad incumbents on record are AbbVie, Amgen and Bristol-Myers Squibb. Direct peers are AnaptysBio, Provention Bio, Arcturus Therapeutics, Coherus Biosciences, Dice Therapeutics (acquired by Eli Lilly), Arena Pharmaceuticals (acquired by Pfizer) and Viela Bio (acquired by Horizon Therapeutics).
Does Anthera Pharmaceuticals have an API?
No public API is recorded for Anthera Pharmaceuticals.
What industry is Anthera Pharmaceuticals in?
Anthera Pharmaceuticals's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 3254.